Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
The purpose of this study is to determine whether exemestane plus everolimus are effective in the treatment of patients who have achieved disease stabilization after induction chemotherapy for hormone-receptor positive metastatic…
- Trial name
- NCT02025712
- Testing
- Exemestane, Everolimus
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Organisation for Oncology and Translational Research
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
UK Ibrance Patient Program (IPP) Study
What are the real-world treatment patterns, patients' characteristics, clinical outcomes and healthcare resource utilisation associated with palbociclib treatment in the 3 years following initiation in United Kingdom patients…
- Trial name
- ROIS (NCT03921866)
- Testing
- Palbociclib
- Where
- 8 sites in United Kingdom
- Volunteers
- 191 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Metastatic Breast Cancer
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination…
- Trial name
- NCT04872166
- Testing
- BTX-A51
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- Edgewood Oncology Inc.
ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer
The primary objective of this expanded access program (EAP) is to provide early access to giredestrant for participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) early breast…
- Trial name
- NCT07643831
- Testing
- Giredestrant
- Where
- 9 sites in United States
- Sponsor
- Genentech, Inc.
Metastatic Breast Cancer, Advanced Breast Cancer
Halaven Patient Registry (Metastatic Breast Cancer, MBC)
Since the first marketing authorization in the world in November 2010 granted by US FDA, Halaven has been approved for clinical use in more than 40 countries worldwide, including many Asian countries, e.g.
- Trial name
- NCT03245112
- Testing
- Eribulin Mesylate
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Chang Gung Memorial Hospital
Breast Cancer
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
This is an open-label, two-stage, multi-arm Phase 1 study designed to evaluate the safety and preliminary efficacy of combining niraparib with four standard chemotherapy regimens used to treat TNBC.
- Trial name
- NCT04762901
- Testing
- Niraparib, Doxorubicin, Cyclophosphamide
- Sponsor
- Wake Forest University Health Sciences
Advanced Solid Tumors With and Without Brain Metastases
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases).
- Trial name
- NCT00539383
- Testing
- ANG1005
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Angiochem Inc
Breast Cancer, Breast Neoplasms
Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer
This study tests whether special imaging goggles can help surgeons find lymph nodes that may be left behind during breast cancer surgery.
- Conditions
- Breast Cancer, Breast Neoplasms, Sentinel Lymph Node, Lymphatic Metastasis
- Trial name
- AR4SLN (NCT07696754)
- Testing
- Augmented-reality ICG fluorescence second-look imaging
- Where
- North Macedonia
- Volunteers
- 30 people
- Sponsor
- Ss. Cyril and Methodius University of Skopje
Breast Cancer, Ovarian Cancer
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT06738966
- Testing
- BL0175
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Metastatic Breast Cancer
Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer
This is a phase II, exploratory, open-label, single arm study of BYL719 monotherapy, a selective phosphatidylinositol 3-kinase (PI3K) alpha inhibitor, in adult patients with advanced metastatic breast cancer progressing after…
- Trial name
- PIKNIC (NCT02506556)
- Testing
- BYl719
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Metastatic Breast Cancer
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy.
- Trial name
- NCT00337103
- Testing
- Eribulin Mesylate, Capecitabine
- Where
- 169 sites in United States, Argentina and 21 more
- Volunteers
- 1,276 people
- Sponsor
- Eisai Inc.
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
HER2-positive Breast Cancer
Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer
To evaluate the safety, biodistribution, radiation dosimetry, and uptake in tumor lesions of patients with Her2-positive metastatic breast cancer after injection of [131I]/[68Ga]SGMIB-ZT-199.
- Trial name
- NCT05982626
- Testing
- 68Ga/131I-SGMIB-ZT-199
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Huashan Hospital
Metastatic Breast Cancer
Platinum Rechallenge in Patients With Platinum-sensitive mTNBC
Platinum Retreated in Patients with Platinum Sensitive mTNBC
- Trial name
- NCT02607215
- Testing
- Vinorelbine, DDP
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Fudan University
Painful Bone Metastases, Breast Carcinoma
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
This study will evaluate treatment with High Intensity Focused Ultrasound (HIFU)in combination with ThermoDox (liposomal doxorubicin) is safe and effective in reducing pain for patients with painful bone metastases.
- Conditions
- Painful Bone Metastases, Breast Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01640847
- Testing
- High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox
- Sponsor
- Imunon
Non-metastatic Breast Cancer
Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy
Breast cancer is the most frequently diagnosed cancer in the world. In France, 58,000 new cases were detected in 2018. Breast cancer is therefore the most common cancer in women.
- Trial name
- ARIANE (NCT06400849)
- Testing
- cryotherapy alone of the upper or lower limbs, cryotherapy and crompression of the upper or lower limbs
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Antoine Lacassagne
Solid Tumor, Adult, Pancreatic Cancer
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.
- Conditions
- Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer
- Trial name
- AGADIR (NCT03915678)
- Testing
- Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
- Where
- 11 sites in France
- Volunteers
- 247 people
- Sponsor
- Institut Bergonié
Hormone-sensitive Metastatic Breast Cancer
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in human beings show that this drug can make a difference in the way anti-estrogens work in hormone-sensitive breast cancers.
- Trial name
- NCT01205685
- Testing
- OSI-906, Erlotinib, Letrozole
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms
A Safety Study of SGN-LIV1A in Breast Cancer Patients
This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
- Conditions
- HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
- Trial name
- NCT01969643
- Testing
- ladiratuzumab vedotin, Trastuzumab
- Where
- 38 sites in United States
- Volunteers
- 290 people
- Sponsor
- Seagen Inc.
Breast Cancer
Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
The purpose of this study is to assess whether expression of not only POLQ/Polθ, but also Shieldin complex and/or 53BP1 are correlated with primary and/or acquired resistance to PARPi (Poly(ADP-Ribose) Polymerases inhibitors) in…
- Trial name
- REPARP (NCT05378204)
- Testing
- Main study:, Sub-study:
- Where
- 25 sites in France
- Volunteers
- 120 people
- Sponsor
- Institut Claudius Regaud
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.